

MnVFC Announcement

Date: July 31, 2025

To: MnVFC Providers

From: MnVFC Program

Re: **RSV monoclonal antibody ordering, Abrysvo available for maternal vaccination**

Please route to:

- Clinical supervisor
- Medical director
- Clinic manager
- Clinic staff
- Pharmacy
- Vaccine staff

RSV monoclonal antibody ordering

Nirsevimab (Beyfortus) will be available to order via the Minnesota Vaccine for Children (MnVFC) program soon. Information about how to order nirsevimab is included below.

Another RSV monoclonal antibody product, clesrovimab, was approved by the ACIP in June, however this new product is not yet available through the MnVFC program because the CDC director has yet to approve the recommendations. Expect to start the season only with nirsevimab until clesrovimab is fully approved and added to the VFC contract. We will send an announcement when that happens.

How to order

Providers will place a request for the doses they expect to need in the initial rollout of the season (through Oct.) in a special event in MIIC. **The event will be open from Aug. 4 to Aug. 15.** Login to MIIC and place your requests during that time to ensure timely distribution.

Only order doses that you have the capacity to store. If you realize you need more doses than you initially requested, you can submit additional requests for more doses at any time. We will process orders as we are given access to doses from the CDC, so sites might receive a few small shipments throughout the initial rollout period. You can check the status of your requests at any time in MIIC.

We plan to have at least one more special event after October to capture doses needed later in the season. Watch for more communications as the season progresses.

Review our [User Guide: Special Event Vaccine Request \(PDF\)](#) (www.health.state.mn.us/people/immunize/miic/train/specrequest.pdf) for more information.

How many doses to order

We recommend adding the following values to estimate your need:

- Any doses borrowed last season (refer to your borrowing report).
- Any 100mg doses for babies born since the end of last RSV season and for children aged 8-19 months entering their second RSV season who are at increased risk of severe RSV disease.
- Any 50mg doses for newborns you expect to be born during this RSV season (Oct. to Mar.).

Additional considerations:

- Expected Abrysvo uptake for pregnant patients.
- Parents of babies born over the summer may be eager to get their kids immunized early in the season, so you may need more 100mg doses earlier in the season.

Birth hospital enrollment

The MnVFC program is interested in enrolling birthing hospitals to support timely immunization against RSV. Information on enrollment is available at [How to Enroll in the MnVFC Program](#) (www.health.state.mn.us/people/immunize/hcp/mnvfc/basics.html).

MnVFC Abrysvo available to order for maternal RSV vaccination

Abrysvo, the Pfizer RSV vaccine that is approved for pregnant people, will be available to order for MnVFC-eligible pregnant teens aged 18 and younger on Aug. 1. Abrysvo should be given to pregnant people at 32 to 36 weeks gestation from September through January to help protect the newborn infant from RSV. You can order this product starting Aug. 1, ahead of the administration window, to ensure you have stock ready on Sept. 1.

Babies born at least two weeks after the birthing parent's vaccination with Abrysvo should not receive RSV monoclonal antibody (nirsevimab [beyfortus] or clesrovimab) except in rare circumstances.

Abrysvo will be on the MnVFC order form in MIIC on Aug. 1. It is available in individual single dose vials. Please consider your patient population when placing orders. For sites that have multiple RSV products, make sure to educate staff on the different uses and indications to avoid vaccination errors. Please keep in mind that Arexvy (GSK) is not approved for pregnant people.

MnVFC Program
651-201-5522 or 1-800-657-3970
www.health.state.mn.us/vfc
health.mnvfc@state.mn.us